BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 20694143)

  • 1. Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease.
    Jung O; Jansen F; Mieth A; Barbosa-Sicard E; Pliquett RU; Babelova A; Morisseau C; Hwang SH; Tsai C; Hammock BD; Schaefer L; Geisslinger G; Amann K; Brandes RP
    PLoS One; 2010 Aug; 5(8):e11979. PubMed ID: 20694143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meloxicam fails to augment the reno-protective effects of soluble epoxide hydrolase inhibition in streptozotocin-induced diabetic rats via increased 20-HETE levels.
    Katary MM; Pye C; Elmarakby AA
    Prostaglandins Other Lipid Mediat; 2017 Sep; 132():3-11. PubMed ID: 27596333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble epoxide hydrolase-dependent regulation of myogenic response and blood pressure.
    Sun D; Cuevas AJ; Gotlinger K; Hwang SH; Hammock BD; Schwartzman ML; Huang A
    Am J Physiol Heart Circ Physiol; 2014 Apr; 306(8):H1146-53. PubMed ID: 24561863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease.
    Čertíková Chábová V; Kujal P; Škaroupková P; Varňourková Z; Vacková Š; Husková Z; Kikerlová S; Sadowski J; Kompanowska-Jezierska E; Baranowska I; Hwang SH; Hammock BD; Imig JD; Tesař V; Červenka L
    Kidney Blood Press Res; 2018; 43(2):329-349. PubMed ID: 29529602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats.
    Čertíková Chábová V; Kujal P; Vaňourková Z; Škaroupková P; Sadowski J; Kompanowska-Jezierska E; Tesař V; Hammock B; Imig J; Maxová H; Červenka L; Vaněčková I
    Kidney Blood Press Res; 2019; 44(6):1493-1505. PubMed ID: 31770762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo.
    Kundu S; Roome T; Bhattacharjee A; Carnevale KA; Yakubenko VP; Zhang R; Hwang SH; Hammock BD; Cathcart MK
    J Lipid Res; 2013 Feb; 54(2):436-47. PubMed ID: 23160182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reno-protective mechanisms of epoxyeicosatrienoic acids in cardiovascular disease.
    Elmarakby AA
    Am J Physiol Regul Integr Comp Physiol; 2012 Feb; 302(3):R321-30. PubMed ID: 22116511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of soluble epoxide hydrolase counteracts the development of renal dysfunction and progression of congestive heart failure in Ren-2 transgenic hypertensive rats with aorto-caval fistula.
    Červenka L; Melenovský V; Husková Z; Škaroupková P; Nishiyama A; Sadowski J
    Clin Exp Pharmacol Physiol; 2015 Jul; 42(7):795-807. PubMed ID: 25969338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epoxyeicosatrienoic acid administration or soluble epoxide hydrolase inhibition attenuates renal fibrogenesis in obstructive nephropathy.
    Noh MR; Jang HS; Salem FE; Ferrer FA; Kim J; Padanilam BJ
    Am J Physiol Renal Physiol; 2023 Feb; 324(2):F138-F151. PubMed ID: 36475868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal Ischemia/Reperfusion Injury in Soluble Epoxide Hydrolase-Deficient Mice.
    Zhu Y; Blum M; Hoff U; Wesser T; Fechner M; Westphal C; Gürgen D; Catar RA; Philippe A; Wu K; Bubalo G; Rothe M; Weldon SM; Dragun D; Schunck WH
    PLoS One; 2016; 11(1):e0145645. PubMed ID: 26727266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats.
    Kujal P; Čertíková Chábová V; Škaroupková P; Husková Z; Vernerová Z; Kramer HJ; Walkowska A; Kompanowska-Jezierska E; Sadowski J; Kitada K; Nishiyama A; Hwang SH; Hammock BD; Imig JD; Červenka L
    Clin Exp Pharmacol Physiol; 2014 Mar; 41(3):227-37. PubMed ID: 24471737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of haem oxygenase in the renoprotective effects of soluble epoxide hydrolase inhibition in diabetic spontaneously hypertensive rats.
    Elmarakby AA; Faulkner J; Pye C; Rouch K; Alhashim A; Maddipati KR; Baban B
    Clin Sci (Lond); 2013 Oct; 125(7):349-59. PubMed ID: 23611540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crosstalk between adenosine receptors and CYP450-derived oxylipins in the modulation of cardiovascular, including coronary reactive hyperemic response.
    Nayeem MA; Hanif A; Geldenhuys WJ; Agba S
    Pharmacol Ther; 2022 Dec; 240():108213. PubMed ID: 35597366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain model.
    Goswami SK; Inceoglu B; Yang J; Wan D; Kodani SD; da Silva CA; Morisseau C; Hammock BD
    Toxicol Appl Pharmacol; 2015 Dec; 289(3):419-27. PubMed ID: 26522832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic disruption of soluble epoxide hydrolase is protective against streptozotocin-induced diabetic nephropathy.
    Chen G; Xu R; Wang Y; Wang P; Zhao G; Xu X; Gruzdev A; Zeldin DC; Wang DW
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(5):E563-75. PubMed ID: 22739108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced coronary reactive hyperemia in mice was reversed by the soluble epoxide hydrolase inhibitor (t-AUCB): Role of adenosine A
    Hanif A; Edin ML; Zeldin DC; Morisseau C; Falck JR; Ledent C; Tilley SL; Nayeem MA
    Prostaglandins Other Lipid Mediat; 2017 Jul; 131():83-95. PubMed ID: 28890385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of soluble epoxide hydrolase attenuates a high-fat diet-mediated renal injury by activating PAX2 and AMPK.
    Luo Y; Wu MY; Deng BQ; Huang J; Hwang SH; Li MY; Zhou CY; Zhang QY; Yu HB; Zhao DK; Zhang G; Qin L; Peng A; Hammock BD; Liu JY
    Proc Natl Acad Sci U S A; 2019 Mar; 116(11):5154-5159. PubMed ID: 30804206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of cytochrome P450-epoxygenase and soluble epoxide hydrolase in the regulation of vascular response.
    Nayeem MA; Geldenhuys WJ; Hanif A
    Adv Pharmacol; 2023; 97():37-131. PubMed ID: 37236764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy.
    Kim J; Yoon SP; Toews ML; Imig JD; Hwang SH; Hammock BD; Padanilam BJ
    Am J Physiol Renal Physiol; 2015 Jan; 308(2):F131-9. PubMed ID: 25377915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice.
    Roche C; Guerrot D; Harouki N; Duflot T; Besnier M; Rémy-Jouet I; Renet S; Dumesnil A; Lejeune A; Morisseau C; Richard V; Bellien J
    Prostaglandins Other Lipid Mediat; 2015 Jul; 120():148-54. PubMed ID: 26022136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.